Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Cell lines</td><td align="center">IC<sub>50</sub> (nM)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">OE19</td><td align="center">188</td></tr><tr><td align="left">NCI-N87</td><td align="center">34</td></tr><tr><td align="left">BT474</td><td align="center">236</td></tr><tr><td align="left">ESO26</td><td align="center">433</td></tr><tr><td align="left">OE33</td><td align="center">&gt;1,000</td></tr><tr><td align="left">MKN7</td><td align="center">&gt;1,000</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

IC<sub>50</sub> values of the various ERBB2-amplified gastroesophageal and breast cancer cells treated with lapatinib.

Evidence-Based Complementary and Alternative Medicine

tab1

Table 1

Table 1: Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib 